Co-expression Network Analysis Identifies Fourteen Hub Genes Associated with Prognosis in Clear Cell Renal Cell Carcinoma

Abstract

Renal cancer is a common genitourinary malignance, of which clear cell renal cell carcinoma (ccRCC) has high aggressiveness and leads to most cancer-related deaths. Identification of sensitive and reliable biomarkers for predicting tumorigenesis and progression has great significance in guiding the diagnosis and treatment of ccRCC. Here, we identified 2397 common differentially expressed genes (DEGs) using paired normal and tumor ccRCC tissues from GSE53757 and The Cancer Genome Atlas (TCGA). Then, we performed weighted gene co-expression network analysis and protein-protein interaction network analysis, 17 candidate hub genes were identified. These candidate hub genes were further validated in GSE36895 and Oncomine database and 14 real hub genes were identified. All the hub genes were up-regulated and significantly positively correlated with pathological stage and histologic grade of ccRCC. Survival analysis showed that the higher expression level of each hub gene tended to predict a worse clinical outcome. ROC analysis showed that all the hub genes can accurately distinguish between tumor and normal samples, and between early stage and advanced stage ccRCC. Moreover, all the hub genes were positively associated with distant metastasis, lymph node infiltration, tumor recurrence and the expression of MKi67, suggesting these genes might promote tumor proliferation, invasion and metastasis. Furthermore, the functional annotation demonstrated that most genes were enriched in cell-cycle related biological function. In summary, our study identified 14 potential biomarkers for predicting tumorigenesis and progression, which might contribute to early diagnosis, prognosis prediction and therapeutic intervention.

Keywords

bioinformatics / clear cell renal cell carcinoma / weighted gene co-expression network analysis / biomarker

References

[1] SiegelRL, MillerKD, JemalA. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34

[2] LjungbergB, BensalahK, CanfieldS, et al.. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol, 2015, 67(5): 913-924

[3] PierorazioPM, JohnsonMH, PatelHD, et al.. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. J Urol, 2016, 196(4): 989-999

[4] BazziWM, SjobergDD, FeuersteinMA, et al.. Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. J Urol, 2015, 193(6): 1911-1916

[5] HsiehJJ, PurdueMP, SignorettiS, et al.. Renal cell carcinoma. Nat Rev Dis Primers, 2017, 3: 17009

[6] ZhaoE, LiL, ZhangW, et al.. Comprehensive characterization of immune- and inflammation-associated biomarkers based on multi-omics integration in kidney renal clear cell carcinoma. J Transl Med, 2019, 17(1): 177

[7] GuanLY, TanJF, LiH, et al.. Biomarker identification in clear cell renal cell carcinoma based on miRNA-seq and digital gene expression-seq data. Gene, 2018, 647: 205-212

[8] TavazoieS, HughesJD, CampbellMJ, et al.. Systematic determination of genetic network architecture. Nat Genet, 1999, 22(3): 281-285

[9] LangfelderP, HorvathS. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 2008, 9: 559

[10] ClarkeC, MaddenSF, DoolanP, et al.. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis, 2013, 34(10): 2300-2308

[11] WangL, TangH, ThayanithyV, et al.. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res, 2009, 69(24): 9490-9497

[12] GuHY, YangM, GuoJ, et al.. Identification of the Biomarkers and Pathological Process of Osteoarthritis: Weighted Gene Co-expression Network Analysis. Front Physiol, 2019, 10: 275

[13] ChenL, YuanL, QianK, et al.. Identification of Biomarkers Associated With Pathological Stage and Prognosis of Clear Cell Renal Cell Carcinoma by Coexpression Network Analysis. Front Physiol, 2018, 9: 399

[14] FicarraV, SchipsL, GuilleF, et al.. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer, 2005, 104(5): 968-974

[15] HorvathS, DongJ. Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol, 2008, 4(8): e1000117

[16] HuangDW, ShermanBT, LempickiRA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009, 4(1): 44-57

[17] GoelMK, KhannaP, KishoreJ. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res, 2010, 1(4): 274-278

[18] TangZ, LiC, KangB, et al.. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017, 45(W1): W98-W102

[19] SingT, SanderO, BeerenwinkelN, et al.. ROCR: visualizing classifier performance in R. Bioinformatics, 2005, 21(20): 3940-3941

[20] GayedBA, YoussefRF, BagrodiaA, et al.. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU Int, 2014, 113(4): 668-673

[21] TilkiD, NguyenHG, Dall’EraMA, et al.. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol, 2014, 66(3): 577-583

[22] GospodarowiczMK, MillerD, GroomePA, et al.. The process for continuous improvement of the TNM classification. Cancer, 2004, 100(1): 1-5

[23] XuJ, LatifS, WeiS. Metastatic renal cell carcinoma presenting as gastric polyps: A case report and review of the literature. Int J Surg Case Rep, 2012, 3(12): 601-604

[24] FrankI, BluteML, ChevilleJC, et al.. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol, 2002, 168(6): 2395-400

[25] ChenL, YuanLS, WangYZ, et al.. Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma. Int J Biol Sci, 2017, 13(11): 1361-1372

[26] YuanL, ChenL, QianK, et al.. Co-expression network analysis identified six hub genes in association with progression and prognosis in human clear cell renal cell carcinoma (ccRCC). Genom Data, 2017, 14: 132-140

[27] WangY, ChenL, WangG, et al.. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis. J Cell Physiol, 2019, 234(7): 10225-10237

[28] DachineniR, AiGQ, KumarDR, et al.. Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention. Mol Cancer Res, 2016, 14(3): 241-252

[29] LeiCY, WangW, ZhuYT, et al.. The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer. Urol Oncol, 2016, 34(5): 237.e1-10

[30] MoML, ChenZ, LiJ, et al.. Use of serum circulating CCNB2 in cancer surveillance. Int J Biol Markers, 2010, 25(4): 236-242

[31] DuxburyMS, WhangEE. RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun, 2007, 354(1): 190-196

[32] ZhangK, HuS, WuJ, et al.. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer, 2009, 8: 11

[33] LiuX, ZhouB, XueL, et al.. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer, 2007, 6(5): 374-381

[34] GartelAL. FOXM1 in Cancer: Interactions and Vulnerabilities. Cancer Res, 2017, 77(12): 3135-3139

[35] KooCY, MuirKW, LamEW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta, 2012, 1819(1): 28-37

[36] GuoL, DingZ, HuangN, et al.. Forkhead Box M1 positively regulates UBE2C and protects glioma cells from autophagic death. Cell Cycle, 2017, 16(18): 1705-1718

[37] Hu GH, Yan ZW, Zhang C, et al. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression. J Exp Clin Cancer Res, 2019,38

[38] KhongkowP, GomesAR, GongC, et al.. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene, 2016, 35(8): 990-1002

[39] Kalimutho M, Sinha D, Jeffery J, et al. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Mol Med, 2018,10(9)

[40] LiY, ZhangZF, ChenJD, et al.. VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res, 2010, 2(3): 296-308

[41] van GijnSE, WierengaE, van den TempelN, et al.. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. Oncogene, 2019, 38(6): 852-867

[42] HuP, ChenX, SunJ, et al.. siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep, 2015, 35(1): e00170

[43] FuHL, ShaoL. Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells. Eur Rev Med Pharmacol Sci, 2016, 20(6): 1071-1079

[44] GhaffariK, HashemiM, EbrahimiE, et al.. BIRC5 Genomic Copy Number Variation in Early-Onset Breast Cancer. Iran Biomed J, 2016, 20(4): 241-245

[45] RenQ, JinB. The clinical value and biological function of PTTG1 in colorectal cancer. Biomed Pharmacother, 2017, 89: 108-115

[46] ZhangQ, SuRX, ShanC, et al.. Non-SMC Condensin I Complex, Subunit G (NCAPG) is a Novel Mitotic Gene Required for Hepatocellular Cancer Cell Proliferation and Migration. Oncol Res, 2018, 26(2): 269-276